Citations

Clear

4510 citation(s) found for "Scott, C".

Determining the Impact of Voxel Size on the Clinical Utility of Quantitative Susceptibility Imaging in Multicenter Clinical Trials
Przybelski, Scott A. , Borowski, Bret, Senjem, Matthew L., Cogswell, Petrice M, Vemuri, Prashanthi, Kantarci, Kejal, Jack, Clifford R., Arani, Arvin , Senjem, Matthew L. , Cogswell, Petrice M. , Vemuri, Prashanthi , Kantarci, Kejal , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_105922 Get It

Abstract Background T2*‐weighted imaging is of paramount importance for patient treatment eligibility and safety monitoring in anti‐amyloid pharmaceutical clinical trials and clinical care. Recently with the adoption of multi‐echo GRE (GRE) sequences, susceptibility weighted imaging (SWI), and quantitative susceptibility mapping (QSM) can be obtained in the same acquisition. In 2024, the QSM Consensus Organization Committee released a white paper recommending at least 1 mm isotropic voxel size for QSM. In clinical workflows microbleed detection is performed with higher in‐plane resolution (0.5x0.5mm 2 ), and large out‐of‐plane resolution (∼1.8mm), which was used in the ADNI4 protocol. In the CLARiTI protocol, a 1mm isotropic resolution was adopted. The objective of this work was to compare susceptibility estimates between the ADNI4 (0.5x0.5x1.8mm 3 ) and CLARiTI (1mm 3 ) protocols. Method The ADNI4 and CLARiTI QSM protocols were acquired on forty‐seven subjects (33 cognitively unimpaired (CU), 14 cognitively impaired (CI), in the same scan session. The groups were defined by their Clinical Demential Rating (CDR) global score (CDR global = 0 for CU, and CDR global >= 0.5 for CI subjects). QSM images were generated using publically available software (STI Suite, UC Berkeley). Mean susceptibility values in atlas regions were compared. Result Significant group differences (CU vs. CI) were observed in the fusiform and middle occipital gyrus with the ADNI4 protocol, only in the rectus with the CLARiTI protocol (Figure 1). These three regions are small in size and closer to surface‐air interfaces, which may have impacted estimation accuracy. However, in the substantia nigra and its sub‐regions (pars compacta and pars reticulata), which shows increased susceptibility in Lewy body disease, the ADNI4 and CLARiTI protocols were in good agreement (r 2 > 0.9) (Figure 2). Conclusion Group differences were observed between the ADNI4 and CLARiTI QSM only in 3 small regions close to surface‐air interfaces in this small dataset. The two techniques showed highly correlated (r 2 = 0.93) estimates in the substantia nigra, a region with high susceptibility due to iron deposition. Strong correlations between the two protocols are encouraging. Radiologists have historically preferred submillimeter in‐plane resolution for microbleed detection, which is more time manageable with anisotropic imaging.
Heterogeneous tau patterns in atypical AD are explained by connectivity‐associated tau progression
Bruin, Hannah de , Groot, Colin , (ADNI), Alzheimer's Disease Neuroimaging Initiative, Barthel, Henryk, Bischof, Gérard N. , Boon, Baayla D.C., Brendel, Matthias, Cash, David M, Day, Gregory S, Dickerson, Brad C., Dyck, Christopher H van, Flier, Wiesje M. van der, Fredericks, Carolyn , Fryer, Tim D. , Giessen, Elsmarieke van de, Gordon, Brian A., Radford, Jonathan Graff, Hansson, Oskar H., Höglinger, Günter U, Hönig, Merle C., Irwin, David J., Jones, P Simon, Josephs, Keith A., Katsumi, Yuta , Lee, Eddie B., Xiong, Chengjie , McGinnis, Scott M., Mecca, Adam P. , O'Brien, John T, O'Dell, Ryan S, Rabinovici, Gil D., Rahmouni, Nesrine, Rosa‐Neto, Pedro, Sabri, Osama, Schott, Jonathan M, Schroeter, Matthias L, Seeley, William W., Servaes, Stijn, Sintini, Irene , Smith, Ruben, Stevenson, Jenna , Strandberg, Olof, Therriault, Joseph, Tideman, Pontus , Touroutoglou, Alexandra , Trainer, Anne, Wekselman, Fattin, Weston, Philip SJ., Whitwell, Jennifer L., Yong, Keir X X, O’Brien, John T. , Rabinovici, Gil D. , Day, Gregory S. , O'Brien, John Tiernan , Day, Gregory S , Xiong, Chengjie , Rabinovici, Gil D , Groot, Colin , Initiative, Alzheimer's Disease Neuroimaging, Blazhenets, Ganna , Boellaard, Ronald , Boon, Baayla D.C. , Brendel, Matthias , Cash, David M. , Coath, William , Dickerson, Brad C., Doering, Elena , Drzezga, Alexander E. , Dyck, Christopher H. van , Eimeren, Thilo van , Flier, Wiesje M. van der , Giessen, Elsmarieke van de , Gordon, Brian A. , Grinberg, Lea T. , Hansson, Oskar , Hobbs, Diana A. , Höglinger, Günter U. , Irwin, David J. , Jones, Peter Simon , Josephs, Keith A. , Joie, Renaud La , Lee, Eddie B, Malpetti, Maura , Mohanty, Rosaleena , Nasrallah, Ilya M. , O’Dell, Ryan S. , Palleis, Carla , Perneczky, Robert , Phillips, Jeffrey S , Putcha, Deepti , Rahmouni, Nesrine , Rosa-Neto, Pedro , Rowe, James B. , Rullmann, Michael , Saur, Dorothee , Schildan, Andreas , Schott, Jonathan M. , Schroeter, Matthias L , Seeley, William W. , Servaes, Stijn , Spina, Salvatore , Stomrud, Erik , Therriault, Joseph , Visser, Denise , Weston, Philip S.J. , Whitwell, Jennifer L. , Wolk, David A. , Yong, Keir , Pijnenburg, Yolande A.L. , Franzmeier, Nicolai , Ossenkoppele, Rik

Mayo Clinic

Alzheimer's & Dementia | January 7, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_104871 Get It

Abstract Background The link between regional tau load and clinical manifestation of Alzheimer's disease (AD) highlights the importance of characterizing spatial tau distribution. In typical (memory‐predominant) AD, the spatial progression of tau pathology mirrors the functional connections from temporal lobe epicenters. However, atypical (non‐amnestic‐predominant) AD variants with heterogeneous tau patterns provide a key opportunity to assess the universality of connectivity as a scaffold for tau progression. Method We included tau‐PET data from 320 subjects with atypical AD, characterized by highly heterogeneous tau patterns ( n = 139 posterior cortical atrophy/PCA‐AD; n = 103 logopenic variant primary progressive aphasia/lvPPA‐AD; n = 35 behavioural variant AD/bvAD; n = 43 corticobasal syndrome/CBS‐AD) from 14 sites, with a subset of patients ( n = 78) having longitudinal tau‐PET data. As an independent sample, we further included regional post‐mortem tau stainings from 93 atypical AD patients from two sites ( n = 19 PCA‐AD, n = 32 lvPPA‐AD, n = 23 bvAD, n = 19 CBS‐AD). Gaussian mixture modeling was used to harmonize different tau‐PET tracers by transforming tau‐PET standardized uptake value ratios to tau positivity probabilities (a uniform scale ranging from 0% to 100%). Using linear regression, we assessed whether 1) brain regions with stronger functional connectivity showed greater covariance in cross‐sectional and longitudinal tau‐PET and post‐mortem tau pathology, and 2) functional connectivity of tau‐PET epicenters and tau‐PET accumulation epicenters was associated with cross‐sectional and longitudinal tau patterns. Result Tau‐PET epicenters—defined as the 5% brain regions with the highest tau load—aligned with clinical variants, e.g. a posterior pattern in PCA‐AD (“visual AD”) and left‐hemispheric temporal predominance in lvPPA‐AD (“language AD”) (Figure 1). More strongly functionally connected regions showed correlated concurrent tau‐PET levels, which was confirmed with post‐mortem data (Figure 2). Moreover, the connectivity profile of tau‐PET epicenters and accumulation epicenters corresponded to tau‐PET progression patterns (Figure 3). Conclusion Our data are consistent with the hypothesis that tau propagation occurs along functional connections originating from local epicenters, across all AD clinical variants. Since tau proteinopathy is a key driver of neurodegeneration and cognitive decline, this finding may advance personalized medicine and participant‐specific endpoints in clinical trials.
Prioritizing patient‐centered research in adult congenital heart disease and pregnancy: Findings from Phase 3 of a multiphase national initiative
Singh, Kashvi , Messmer, Mindi , D’Souza, Rohan , Jackson, Jamie L. , Bravo‐James, Katia, Cortes, Jennifer, Buber, Yonitan, Earing, Michael G. , Abusbeitan, Ayesha, Franklin, Wayne, Leezer, Scott, Phillippi, Ruth, John, Anitha S. , Buber, Jonathan , Jackson, Jamie , Bravo-James, Katia, Buber, Yonitan , John, Anitha , D'Souza, Rohan , Russo, Melissa L. , Cortes, Jennifer

Mayo Clinic

Pregnancy | January 7, 2026 | Volume: 2 | Issue: 1 | Pages: No page available

10.1002/pmf2.70215 | PMID 42597075 Get It

Abstract Background Despite advancements in care, pregnant individuals with congenital heart disease (CHD) face disproportionately high risks. Objectives To address these challenges, a national consortium was established to improve maternal outcomes in CHD through multidisciplinary collaboration and patient engagement. Study design As part of a 2.5‐year multi‐phase consortium initiative, an in‐person research summit followed by three virtual focus groups (Project PHASE 3) was conducted with patients, clinicians, researchers, advocates, and policy representatives. Qualitative data were collected, and reflexive thematic analysis was performed to identify shared priorities. Results A total of 48 individuals participated in the in‐person meeting, including 18 patients (83% female; 11% Black/African American, 17% Asian, 11% Hispanic, 61% White) and 30 clinicians/researchers. An additional 19 patients (100% female; 32% rural/non‐urban; 16% Black/African American, 10% Hispanic, 74% White) participated in virtual focus groups. Key priorities identified included improved patient–healthcare provider communication, expanded access to multidisciplinary and adult CHD‐specialized care, and greater inclusion of patient voices in reproductive planning and research. Focus groups underscored racial disparities in care, limited CHD education for patients of color, and the need for culturally tailored resources. Participants emphasized the importance of representative research cohorts, integration of genetic counseling, and dissemination of research in accessible, plain‐language formats. Conclusions Findings demonstrate the value of integrating patient expertise and partnership in shaping cardio‐obstetric research, care models, and education. Addressing maternal health concerns in CHD research requires both structural changes and community‐driven, inclusive research strategies.
Rationale and design of a randomized, sham-controlled, clinical trial for evaluation of the Edwards APTURE transcatheter shunt system (ALT-FLOW II)
Kereiakes, Dean J, Tedford, Ryan J, Lindenfeld, JoAnn, Gray, William A. , Zahr, Firas, Lurz, Phillip, Hibbert, B., Baron, Suzanne J., Jorde, Ulrich P, Teerlink, John R, Kahwash, Rami , Lilly, S. Mary, Böhm, M, Windecker, S, Butler, Javed, Harrington, Robert A, Tedford, Ryan J. , Hibbert, Benjamin , Jorde, Ulrich P. , Kereiakes, Dean J , Tedford, Ryan J , Zahr, Firas , Hibbert, Benjamin , Teerlink, John R , Kahwash, Rami , Böhm, Michael , Windecker, Stephan , Butler, Javed , Kereiakes, Dean J. , Lindenfeld, JoAnn , Zahr, Firas , Cavalcante, João L. , Lilly, Scott M, Windecker, Stephan , Butler, Javed , Harrington, Robert A.

Mayo Clinic

European Journal of Heart Failure | January 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ejhf/xuaf016 | PMID 41771068 Get It

Abstract Aims Heart failure (HF) with preserved (HFpEF) and mildly reduced (HFmrEF) ejection fraction are prevalent, yet frequently underdiagnosed syndromes associated with high morbidity and mortality, impaired quality of life, and escalating healthcare expenditures. Although guideline-directed medications like SGLT2 inhibitors have been shown to reduce the risk of hospitalization and cardiovascular death, their use remains limited and substantial residual risk persists. This trial aims to evaluate the safety and performance of a novel left-atrium-to-coronary-sinus shunt (Edwards APTURE transcatheter shunt system) in HFpEF and HFmrEF patients. Methods ALT-FLOW II is a prospective multi-centre, randomized, sham-controlled, double-blinded (patient and assessor) trial. Approximately 100 symptomatic HF patients aged ≥18 years with left ventricular ejection fraction >40% and exercise pulmonary capillary wedge pressure (PCWP) ≥25 mm Hg with a PCWP to right atrial pressure gradient ≥8 mm Hg will be randomized 1:1 to the APTURE shunt vs sham control. Key exclusion criteria include severe HF, significant valvular disease, and more than mild right ventricular dysfunction. The primary endpoints are the safety of the APTURE device at 30 days and change in workload-corrected PCWP normalized to bodyweight at 6 months. Secondary endpoints include changes in patient-reported outcomes, and hemodynamic and echocardiographic parameters through 5 years. The trial will also explore the impact of the device on short-term cardiac remodelling and intra-cardiac flow patterns using multi-modality imaging. Conclusions The ALT-FLOW II trial will evaluate the safety and performance of the APTURE system in symptomatic HFpEF and HFmrEF patients with elevated left atrial pressure.
Z-coded social determinants of health and cardiovascular risk among patients receiving dialysis
Alhammouri, Hashim, Ibrahim, Ramzi , AlAsmar, Rahmeh, Dreher, Luke, Almakadma, Abdul Hakim , Pham, Hoang Nhat, Mahmoud, Ahmed K, Awad, K, Abdelnabi, Mahmoud, Salih, Mohammed, Agarwal, Siddharth, Al‐Kindi, Sadeer , Sorajja, Dan , Scott, Luis R, Ayoub, C A, Arsanjani, R A, Awad, Kamal , Al-Kindi, Sadeer , Sorajja, Dan , Ayoub, Chadi , Ibrahim, Ramzi , Al-Asmar, Rahmeh , Dreher, Luke , Pham, Hoang Nhat , Awad, Kamal , Abdelnabi, Mahmoud , Agarwal, Siddharth , Hommos, Musab S. , Arsanjani, Reza

Mayo Clinic

Journal of Nephrology | January 6, 2026 | Volume: 39 | Issue: 3 | Pages: 528-535

10.1093/joneph/aajaf060 | PMID 42189835 Get It

Abstract Introduction Cardiovascular disease (CVD) is the leading cause of death among patients with kidney failure on dialysis. Social determinants of health may worsen this risk but are seldom incorporated into prognostic models. ICD-10 Z-codes provide standardized documentation of social determinants of health, yet their prognostic value in dialysis populations remains uncertain. This study examined whether Z-coded social determinants of health are associated with adverse cardiovascular outcomes and mortality among patients receiving dialysis for kidney failure. Methods A retrospective cohort study was conducted using the TriNetX Research Network (2010–2024), encompassing de-identified data from 103 institutions. Adults with kidney failure on chronic dialysis were stratified by the presence of ICD-10 Z-codes (Z55–Z65). Propensity score matching (1:1) balanced demographics, comorbidities, medications, and laboratory values. Primary outcomes were all-cause mortality and hospitalization; secondary outcomes included acute heart failure, myocardial infarction, stroke, cardiac arrest, bradyarrhythmias, and ventricular tachycardia. Results After matching, mean age was 62 years, and 42.4% were female in the Z-code cohort versus 41.2% in controls. Over one year, mortality occurred in 12.5% versus 10.9% (hazard ratio [HR], 1.22; 95% confidence interval [CI], 1.15–1.29) and all-cause hospitalizations in 57.3% versus 53.1% (HR, 1.22; 95% CI, 1.19–1.26). Cardiovascular complications were consistently higher in Z-coded patients, including heart failure (24.3% vs 20.5%; HR, 1.29), myocardial infarction (8.0% vs 7.1%; HR, 1.19), stroke (6.6% vs 6.2%; HR, 1.13), cardiac arrest (3.8% vs 3.1%; HR, 1.29), and bradyarrhythmias (6.9% vs 5.5%; HR, 1.33). Discussion Among patients with kidney failure, documented Z-coded social risk factors were associated with greater mortality and cardiovascular morbidity. Incorporating social determinants of health documentation into nephrology care may improve risk stratification and inform targeted interventions.
Trends in older adults boarding in US EDs
Sifnugel, Natalia, Cruz, Daniel S. , Jeffery, Molly M, Carr, Brendan, Gettel, C., Jeffery, Molly Moore , Sangal, Rohit B. , Carr, Brendan M. , Dresden, Scott M. , Gettel, Cameron J. , Hwang, Ula

Mayo Clinic

Innovation in Aging | January 3, 2026 | Volume: 9 | Issue: Supplement_2 | Pages: No page available

10.1093/geroni/igaf122.3349 Get It

Abstract Inpatient boarding (holding patients in the emergency department [ED] while awaiting an inpatient bed) is associated with increased risk of delirium, medication safety events, and hospital mortality in older adults. We investigated boarding trends across age strata to determine if older patients had elevated rates compared to younger patients. Administrative data for ED encounters resulting in admission from 3 healthcare systems (2 Midwest, 1 Northeast) from 1/1/19 to 12/31/24 were reviewed. Age was categorized by strata: < 21, 21-64, 65-74, 75-84, and ≥ 85. Based on the CMS Age Friendly Hospital Measures, the proportion of patients boarding for 3+ hours was calculated within each year and age strata. Boarding rates varied substantially by system and age group. At Systems 1 (S1) and 3 (S3), ≥ 85 patients had the highest rates (S1: 54.9%, S3: 70.9% in 2024) and, at System 2 (S2), all adult patients (21+) had similar rates (20.5-22.4% in 2024). Boarding rates increased in all systems over the study period. At S1 and S3, < 21 patients had the highest average yearly increase in boarding (S1: 7.4%, S3: 3.9%). At S2, boarding increased most in ≥ 85 (23.9%). In this multisystem evaluation, approximately one in two older adults experience ED boarding, with the oldest patients (≥ 85) facing the greatest exposure to boarding in recent years. These findings taken alongside known delays and safety risks associated with boarding and patient care complexity amongst the oldest adults may result in disproportionate harm to some of the most vulnerable patients.
Six-Year Trends in ICU Admission, Management, and Outcomes of Chimeric Antigen Receptor T-Cell Patients in the ICU
Rajendram, Prabalini , Stephens, R. Scott , Brown, Anne Rain T., Nates, Joseph L., Dharshan, Ananda, Hensley, Matthew K., Feng, L., McEvoy, Colleen , Ibikunle, Sikemi, Beasley, Melissa, Mead, Elena, Kostelecky, Natalie, Mucha, Simon , Mian, Agrima , Ahmed, Sairah, Tharwani, Arsal, Hill, Brian T. , Lin, Yi, Gutiérrez, Cristina , Initiative, and the Chimeric Antigen Receptor for the ICU (CAR-ICU), Gutierrez, Cristina , Brown, Anne Rain , May, Heather P. , Nates, Joseph L. , Pastores, Stephen M. , Moraes, Alice Gallo de , Hensley, Matthew K. , Ibikunle, Sikemi, Westin, Jason R. , Ahmed, Sairah , Tharwani, Arsal , Herr, Megan M.

Mayo Clinic

Critical Care Medicine | December 30, 2025 | Volume: 54 | Issue: 3 | Pages: 422-434

10.1097/ccm.0000000000007000 | PMID 41467744 Get It

Objectives: To evaluate evolving management, ICU admission, and outcomes for critically ill chimeric antigen receptor (CAR) T-cell patients over a 6-year period. Design: Multicenter retrospective cohort study from January 2018 to September 2023. Setting: Eight U.S. centers. Patients: Adult CAR T-cell patients requiring ICU admission. Interventions: None. Methods: Summary statistics included mean, sd , median, and interquartile range (IQR). Fisher exact test or chi-square test were used to evaluate association between year treated and other categorical variables. Cochran-Armitage test was performed to assess significance of trends across years. Multivariable logistic regression was performed to assess covariates associated with mortality. Measurements and Main Results: Demographics, toxicity management, ICU admission, support modalities, toxicity severity, and survival (ICU, hospital, and 3-mo) were compared year-to-year. From 2018 to 2023, 2238 patients received CAR T cells, with increasing number of patients treated yearly; 398 (17.8%) required ICU care. Of those admitted to the ICU, 66.1% were male, 89.2% had lymphoma, and median age was 64 years (53–71 yr). ICU admission rates declined from 38.5% (95% CI, 31.6–45.8%) in 2018 to 16.4% in 2023 (95% CI, 13.5–19.7%; p < 0.0001). Cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome was the reason for ICU admission in 87.9%. In 2023 vs. 2018, ICU patients were older (median, 65 yr [IQR, 55–73 yr] vs. 58 yr [48–67 yr]; p = 0.003) with higher comorbidity indices (4 [4–6] vs. 3 [2–4]; p = 0.005) and more severe toxicities (≥ grade 3: 90.1% vs. 69.9%; p = 0.004). Corticosteroid use for less severe toxicities (≤ grade 2 toxicity: 73.8% vs. 40.6%; p = 0.0001) and anakinra use (56% vs. 5.5%; p < 0.0001) increased throughout the years. Mortality from cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome remained low (5.5%). Age, Sequential Organ Failure Assessment greater than or equal to 10 at ICU admission, and ICU admission for noncytokine release/neurotoxicity syndrome reasons were associated with hospital mortality (odds ratios, 1.02 [95% CI, 1–1.04; p = 0.046], 4.69 [2.44–9.01; p < 0.0001], and 3.74 [1.91–7.3; p = 0.0001], respectively). Conclusions: ICU admission rates after CAR T-cell treatment are declining. Although ICU patients are older with higher severity of illness and toxicity grades, ICU mortality after CAR T-cell therapy remains low.
The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors
Alexander, S P H , Fabbro, Doriano , Peach, Chloe J. , Gibb, Alasdair J. , Kelly, Eamonn , Mathie, Alistair , Veale, Emma L. , Armstrong, Jane F , Faccenda, Elena , Harding, Simon D , Beuve, Annie, Brouckaert, Peter, Burnett, John C., Friebe, Andreas, Garthwaite, John, Hobbs, Adrian J., Koesling, Doris, Kuhn, Michaela, Leitinger, Birgit , Potter, Lincoln R., Russwurm, Michael, Schmidt, Harald H. H. W., Stasch, Johannes‐Peter, Waldman, Scott A., Alexander, Stephen P H , Mathie, Alistair A , Southan, Christopher , Davies, Jamie A , Bryant, Clare , Farndale, Richard W , Jarvis, Gavin E , Kilpatrick, Laura , Leitinger, Birgit , MacEwan, David , Monie, Tom P , Veale, Emma L , Armstrong, Jane F , Faccenda, Elena , Harding, Simon D , Peach, Chloe J. , Gibb, Alasdair J. , Kelly, Eamonn , Beuve, Annie , Brouckaert, Peter, Burnett, John C., Farndale, Richard, Friebe, Andreas , Garthwaite, John, Hobbs, Adrian J., Koesling, Doris , Kuhn, Michaela, Potter, Lincoln R., Russwurm, Michael, Schmidt, Harald , Stasch, Johannes‐Peter, Waldman, Scott A.

Mayo Clinic

British Journal of Pharmacology | December 30, 2025 | Volume: 182 | Issue: S1 | Pages: No page available

10.1111/bph.70233 | PMID 41461584 Get It

The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear, accessible, and well‐structured, rather than the scope of the content, which spans approximately 500 pages. The Concise Guide summarises the key pharmacological properties of around 1900 human drug targets, and nearly 7000 interactions, involving around 4400 ligands. While the content is a substantially condensed version of the more detailed information and links available at the www.guidetopharmacology.org website, the printed guide serves as a permanent, citable, point‐in‐time record, that remains stable despite ongoing updates to the online database. The full contents of this publication can be found at https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.70233 . The Concise Guides provide expert‐curated recommendations of ‘Gold Standard’ selective pharmacological tools, available either commercially or as donations, which enable the identification of individual drug targets or families of drug targets. While the Concise Guide offers a more streamlined overview, more comprehensive information, including detailed pharmacological profiles and links to multiple online databases, is available through the Guide to Pharmacology website. The 2025/26 edition of the Concise Guide is based on material current as of mid‐2025, and supersedes all previous editions, including the 2023/24 Guide, and earlier Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), and as such provides official IUPHAR classification and nomenclature for human drug targets, where applicable. Catalytic receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein‐coupled receptors, ion channels, nuclear hormone receptors, enzymes and transporters. Each section includes nomenclature guidance, concise summaries, information of the best available pharmacological tools, key references, and suggestions for further reading.
MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor–Resistant Cholangiocarcinoma and Attenuate the IFN Response
Wan, Jinkai , Saatcioglu, Hatice D. , Ellis, Haley , Aguado-Fraile, Elia , Xu, Qin , Kondo, Hiroshi , Manguso, Robert T. , Gritti, Ilaria , Norden, Bryanna L. , Corcoran, Ryan B. , Javle, Milind, Cleary, James M. , Kelley, Robin Katie, Macarulla, Teresa, Oh, Do Youn, Daigle, Scott R., Gliser, Camelia, Pandya, Susan , Tron, Adriana E. , Bardeesy, N., Saatcioglu, Hatice Duygu , Noble, Carolina , Corcoran, Ryan B , Lubner, Sam J , Javle, Milind M , Abou-Alfa, Ghassan K , Cleary, James M , Kelley, R Katie , Borad, Mitesh J , Macarulla, Teresa , Oh, Do-Youn , Daigle, Scott , Gliser, Camelia , Choe, Sung , Tron, Adriana E , Bardeesy, Nabeel , Lubner, Sam Joseph , Javle, Milind , Abou‐Alfa, Ghassan K. , Kelley, Robin Kate , Borad, Mitesh J. , Macarulla, Teresa

Mayo Clinic

Clinical Cancer Research | December 29, 2025 | Volume: 32 | Issue: 5 | Pages: 925-937

10.1158/1078-0432.ccr-25-3284 | PMID 41460204 Get It

Abstract Purpose: Mutant IDH1 (mIDH1) defines a therapeutically targetable subtype of intrahepatic cholangiocarcinoma (ICC), with the mIDH1 inhibitor ivosidenib approved for advanced disease. A subset of patients experiences prolonged disease stabilization; however, the molecular basis for eventual progression remains poorly defined. Experimental Design: We performed molecular profiling of matched baseline and postprogression circulating tumor DNA (ctDNA) samples from patients with mIDH1 ICC enrolled in the ClarIDHy phase III trial. Functional studies were conducted to characterize candidate resistance mechanisms. Results: Longitudinal ctDNA analysis of 18 patients treated with ivosidenib for &gt;6 months revealed emergent genomic alterations in multiple cases. Acquired mutations in mitogen-activated protein kinase (MAPK) pathway genes (KRAS, NRAS, MAP2K1, NF1) were identified in five cases, with instances of concurrent alterations and/or high variant allele fractions (VAF). Additional candidate resistance events included a secondary IDH1 mutation and a hotspot IDH2 mutation, detected at low VAF in the same patient. Functional studies showed that these IDH mutations conferred sustained 2-hydroxyglutarate production and ivosidenib resistance, whereas MAPK activation blunted gene expression induced by ivosidenib plus IFNγ, a key therapeutic output of mIDH1 inhibition. In parallel, baseline ctDNA profiling of 81 patients revealed that ARID1A mutations and elevated mIDH1 VAF were associated with reduced clinical benefit. Conclusions: MAPK pathway alterations represent a recurrent mechanism of resistance to mIDH1 inhibition in ICC, whereas emergent IDH1/IDH2 mutations appear infrequent. Functional data suggest that MAPK-mediated resistance may involve impaired IFN signaling. These results support MAPK-directed combination strategies and highlight the utility of ctDNA profiling to identify predictive and resistance biomarkers in mIDH1-driven ICC.
Multispot white matter hyperintensity pattern as a surrogate marker of cerebral amyloid angiopathy in the population
Raghavan, Sheelakumari, Graff‐Radford, Jonathan, Gunter, Jeffrey L. , Przybelski, Scott A. , Spychalla, Anthony J., Cogswell, Petrice M, Ramanan, Vijay K., Petersen, R., Jack, Clifford R., Vemuri, Prashanthi, Raghavan, Sheelakumari , Graff‐Radford, Jonathan , Cogswell, Petrice M. , Ramanan, Vijay K. , Jack, Clifford R. , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | December 26, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_103092 Get It

Abstract Background White matter hyperintensity topography, particularly posterior confluent and subcortical multispot (WMH‐MS), has been implicated as surrogate imaging biomarker of cerebral amyloid angiopathy (CAA). Usefulness of WMH‐MS for prediction of future cerebral microbleeds (CMB's) has significant clinical implications for anti‐amyloid therapy risk assessment. Our primary goal was to identify the prevalence of positive WMH‐MS status and their utility for predicting the incident CMBs in a population‐based sample. Our secondary goal was to evaluate its usefulness after accounting for amyloid (surrogate for CAA) and WMH burden (surrogate of small vessel disease) which are both risk factors for CMBs. Method We identified 651 participants (mean age (SD) 69.8 (10.0) years, 55% male) from the Mayo Clinic Study of Aging, who had 3T baseline whole brain fluid‐attenuated inversion recovery (FLAIR) MRI and at least two T2*‐weighted gradient recalled echo (GRE) sequences (concomitant with or after FLAIR) which were used to ascertain CMBs. Amyloid positron emission tomography (PiB‐PET) scans were available in 87% of the sample. Visual reads on FLAIR scans were performed using a 4‐point Fazekas rating scale of periventricular and deep WMH (positivity: Fazekas ≥ 2) and a 3‐point MS severity visual scale (positivity: nWMH‐MS > 10 circular or ovoid WMH spots, Figure 1) according to established criteria. Using univariate and multivariable logistic regression, we assessed the independent association of WMH‐MS > 10 and Fazekas ≥ 2 for prediction of incident CMB's. Result The frequency of WMH‐MS pattern was greater in those who developed an incident CMB compared to those who did not develop a CMB (20.8% vs. 2.8%, p < 0.001). Older age and male sex were predictive of incident CMBs (Figure 2A). In univariate models, presence of WMH‐MS pattern but not Fazekas was associated with incident CMBs after adjusting for age and sex. The associations remained significant after additional adjustment for APOE4 , hypertension, number of baseline CMBs (Prior CMB), and amyloid effects (Figure 2B). Conclusion Visually identified WMH‐MS patterns on FLAIR‐MRI were predictive of incident CMBs in this population and may be useful markers of CAA. Future studies evaluating its utility as an additional biomarker of amyloid related imaging abnormalities in clinical trials are necessary.